Skip to main
NAGE

ChromaDex Corp (NAGE) Stock Forecast & Price Target

ChromaDex Corp (NAGE) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Niagen Bioscience is the leader in NAD+ science and healthy-aging research with a unique portfolio of over 100 patents and multiple growth opportunities. These include expansion of their core supplement business, rollout of Niagen IV and at-home injectable kits, and potential use cases in various diseases. Their recent financial results show strong revenue growth, and a recent lawsuit against the FDA could provide a long-term tailwind. Risks include potential slower-than-projected sales growth and unfavorable clinical data. Overall, with a strong portfolio and growth potential, Niagen Bioscience has a positive outlook for investors.

Bears say

Niagen Bioscience is heavily reliant on one key product, Tru Niagen. With the possibility of changes in consumer preferences, competition, and regulatory risks, as well as the potential for stock dilution, there are fundamental uncertainties that may negatively impact the company's revenue and overall financial performance in the coming quarters. The company's decision to expand into the telehealth market with the Niagen Plus platform may bring some operational efficiency, but it may not be enough to mitigate the risks facing their core product and overall business model. Without strong efforts to diversify their product offerings and build a more resilient business model, Niagen Bioscience may struggle to maintain its leadership in the NAD+ science industry and satisfy investor expectations for growth.

ChromaDex Corp (NAGE) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ChromaDex Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ChromaDex Corp (NAGE) Forecast

Analysts have given ChromaDex Corp (NAGE) a Strong Buy based on their latest research and market trends.

According to 2 analysts, ChromaDex Corp (NAGE) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ChromaDex Corp (NAGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.